COHERUS BIOSCIENCES IS A LEADER IN DEVELOPING AND COMMERCIALIZING BIOSIMILAR DRUGS OF THE HIGHEST QUALITY AND VALUE. THIS IMPORTANT NEW PHARMACEUTICAL CATEGORY, SUPPORTED BY REGULATORS IN THE US, EUROPE AND ASIA, IS RAPIDLY WINNING THE TRUST OF PATIENTS AND HEALTHCARE PROVIDERS.
We have a unique combination of intellectual assets, commercial capabilities, global reach and strategic focus required to successfully develop and market biosimilar drugs. Founded in 2010 as a pure-play biosimilar platform company, Coherus is devoted to expanding patient access to these life-changing therapeutics in major regulated markets around the world. Indeed, we believe Coherus is the only standalone biosimilars company with the insights and assets needed to succeed in this mission.
Our platform includes world-class capabilities in process science, analytical characterization, protein production, and clinical and regulatory development. What’s more, our scientific and commercial goals are grounded in the expertise of an elite team of industry veterans, supported from the outside by top-tier global biopharmaceutical partners.
LEADERS AT COHERUS HELPED DEVELOP THE BIOLOGIC DRUGS THAT TURNED BIOTECH FROM A NICHE INTO MAINSTREAM MEDICINE. IT’S THE IDEAL TEAM TO LEAD THE TRANSITION TO BIOSIMILAR THERAPEUTICS.